Exploring the Impact of Sacituzumab Govitecan 180 mg for Cancer Treatment in India
What is Sacituzumab Govitecan? Sacituzumab Govitecan 180 mg, also known as Trodelvy. It is an antibody-drug conjugate (ADC) that targets the protein Trop-2, found on the surface of cancer cells. This protein is responsible for the growth and spread of cancer, and by targeting it, Sacituzumab Govitecan can effectively stop the cancer cells from multiplying and spreading. The drug is a combination of a monoclonal antibody, sacituzumab, and a chemotherapy drug, which makes it a highly effective treatment for various types of cancer. This drug has shown promising results in treating advanced forms of breast, lung, and bladder cancer, giving hope to thousands of patients and their families. Mechanism of action:- Sacituzumab Govitecan 180 mg works in a two-pronged approach. Firstly, the antibody portion of the drug targets the cancer cells, allowing for specific delivery of chemotherapy to the tumor site. This helps in minimizing the damage to healthy cells and reduces the...